The Question Is Whether To Buy Or Not To Buy Ocuphire Pharma Inc (NASDAQ: OCUP)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

Ocuphire Pharma Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $2.18 and fluctuated between $2.3300 as its day high and $2.1400 as its day low. The current market capitalization of Ocuphire Pharma Inc is $54.09M. A total of 0.72 million shares were traded on the day, compared to an average of 205.82K shares.

In the most recent transaction, Jhaveri Nirav S. bought 10,000 shares of OCUP for 2.10 per share on Mar 21 ’24. After the transaction, the Chief Financial Officer now owns 150,000 company shares. In a previous transaction on Mar 21 ’24, SCHACHLE JOSEPH K bought 2,000 shares at 2.05 per share. OCUP shares that Chief Operating Officer owns now total 2,000.

Among the insiders who bought shares, Magrath George acquired of 25,000 shares on Mar 18 ’24 at a per-share price of $1.96. This resulted in the Chief Executive Officer holding 425,000 shares of OCUP after the transaction.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, OCUP has a high of $6.60 and a low of $1.85.

As of this writing, OCUP has an earnings estimate of -$0.13 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.01 per share and a lower estimate of -$0.23. The company reported an EPS of $0.25 in the last quarter, which was 213.60% higher than expectations of -$0.22.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. OCUP’s latest balance sheet shows that the firm has $24.75M in Cash & Short Term Investments as of fiscal 2021. There were $538.00k in debt and $3.85M in liabilities at the time. Its Book Value Per Share was $2.08, while its Total Shareholder’s Equity was $22.22M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OCUP is Buy with a score of 5.00.

Most Popular

Related Posts